12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-3102: Phase III started

Merck disclosed in its 2012 earnings that it began multiple double-blind Phase III trials to evaluate once-weekly oral...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >